Europe Liquid Biopsy Market

Market Introduction

Liquid biopsy is a revolutionary technology that is opening up various perspectives. The technology consists of isolation and detection of circulating tumor cells, circulating tumor DNA and exosomes, which provides genomic information of the cancer patients. Liquid biopsy are used in cancer diagnosis in order to study response or resistance to given treatments.

Moreover, the European Society for Medical Oncology (ESMO) is the leading professional organization for medical oncology, is continuing to help oncology professionals by helping them to deliver optimal care to their cancer patients in such situations. The impact of the COVID-19 pandemic on cancer patients is high in terms of anxiety, fear, and psychological distress. However, due to growing COVID-19, the supply of diagnostics kits and assays are delayed because of growing quarantine time and shutting down all business operations. Europe is facing the massive impact of an outbreak due to exponential growth of infections in the region. As per data published by public sources, till March 26, Europe had an estimated 250,000 number of infected patients in the region. The outbreak badly hits countries such as Italy, Spain, Germany, France, and the UK.

Europe Liquid Biopsy Strategic Insights

Strategic insights for the Europe Liquid Biopsy provides data-driven analysis of the industry landscape, including current trends, key players, and regional nuances. These insights offer actionable recommendations, enabling readers to differentiate themselves from competitors by identifying untapped segments or developing unique value propositions. Leveraging data analytics, these insights help industry players anticipate the market shifts, whether investors, manufacturers, or other stakeholders. A future-oriented perspective is essential, helping stakeholders anticipate market shifts and position themselves for long-term success in this dynamic region. Ultimately, effective strategic insights empower readers to make informed decisions that drive profitability and achieve their business objectives within the market.

Europe Liquid Biopsy Report Scope

Europe Liquid Biopsy Regional Insights

The geographic scope of the Europe Liquid Biopsy refers to the specific areas in which a business operates and competes. Understanding local distinctions, such as diverse consumer preferences (e.g., demand for specific plug types or battery backup durations), varying economic conditions, and regulatory environments, is crucial for tailoring strategies to specific markets. Businesses can expand their reach by identifying underserved areas or adapting their offerings to meet local demands. A clear market focus allows for more effective resource allocation, targeted marketing campaigns, and better positioning against local competitors, ultimately driving growth in those targeted areas.

The Europe liquid biopsy market is expected to reach US$ 2,251.12 Mn in 2027 from US$ 1,017.60 Mn in 2018. The market is anticipated to grow with a CAGR of 9.5% from 2019-2027. Factors driving the market growth include government and global health organizations initiatives. However, low sensitivity of liquid biopsy is likely to have a negative impact on market growth.

Key Market Segments

By product & services, the reagents and kits segment accounted for the largest market share in the Europen liquid biopsy market in 2018. In terms of sample, the blood based segment held the largest market share of the liquid biopsy market by 2027. By circulating biomarker, the circulating tumor cells (CTC) segment accounted for the largest market share in the Europen liquid biopsy market in 2019. By 2027, the oncology segment accounted for the largest market share by application. Furthermore, in terms of end user, the reference laboratories segment held the largest market share of the liquid biopsy market by 2027.

Major Sources and Companies Listed

Some of the major primary and secondary sources for liquid biopsy market included in the report are, Biotechnology and Biological Sciences Research Council (BBSRC), British Journal of Surgery (BJS), Cancer Center Amsterdam (CCA), International Diabetes Federation (IDF), and among others.

Reasons to buy the report

• To understand the liquid biopsy market landscape and identify market segments that are most likely to guarantee a strong return
• Stay ahead of the race by comprehending the ever-changing competitive landscape for liquid biopsy market
• Efficiently plan M&A and partnership deals in liquid biopsy market by identifying market segments with the most promising probable sales
• Helps to take knowledgeable business decisions from perceptive and comprehensive analysis of market performance of various segment form liquid biopsy market
• Obtain market revenue forecast for market by various segments from 2018-2027 in Europe region.

EUROPE LIQUID BIOPSY MARKET SEGMENTATION

By Product & Service

• Equipment
• Reagents & Kits
• Services

By Sample

• Blood Based
• Urine Based
• Other samples

By Circulating Biomarker

• Circulating Tumor Cells (CTC)
• Exosomes
• Free Nucleic Acid

By Application

• Noninvasive Prenatal Testing (NIPT)
• Oncology
• Transplant Diagnostics
• Other Applications

By End User

• Academic & Research Institutes
• Hospitals
• Reference Laboratories
• Other End Users

By Geography

•             Europe

• UK
• Germany
• France
• Italy
• Spain

Company Profiles

• F. Hoffmann-la Roche ltd
• Inivata Ltd
• LungLife AI, Inc.
• Exosome Diagnostics
• MDxHealth